Objective-To compare the efficacy and safety of oral acyclovir (400 mg twice daily) with oral isoprinosine (500 mg twice daily) in the suppression of recurrent genital herpes.
Introduction
Recurrent genital herpes (RGH) infections are becoming increasingly common and are often a source of considerable physical discomfort and emotional disturbance in affected patients. Numerous different treatments have been suggested for the management of patients with genital herpes; these include antiviral drugs and immuno-modulators.' 2 The majority of these preparations have been shown in clinical trials to be ineffective. However, both acyclovir and inosine pranobex/isoprinosine have been reported to reduce the frequency of recurrences in separate controlled trials.3"'l
The aim of this study was to compare the efficacy and tolerance of these oral agents in the suppression of RGH infections in comparison with placebo.
Patients and methods Study design
This was a multi-centre, double-blind, doubledummy, randomised, controlled, parallel group trial in patients with a history of RGH. The study was approved by the Ethical Committee of each hospital prior to patient entry.
Patient selection and exclusion Patients aged 16 years or more with a known history of frequent attacks of recurrent herpes genitalis (six or more per year) were invited to participate. A culture positive recurrence during the observation period was necessary for inclusion in the study. Women who were not adequately protected against pregnancy, and patients of either sex with known HIV infection, other causes of immunosuppression, a history of gastrointestinal malabsorption, renal disease with a creatinine clearance below 50 ml/min, gout or hyperuricaemia, or severe atopic eczema were excluded. All patients were informed of the experimental nature of the treatment and were asked to give their consent to participate, prior to entering the study.
Patient management Eligible patients were initially observed without treatment for 8 weeks. During this observation period, they were required to complete daily diary cards detailing symptoms and signs of recurrences. They were asked to return to the clinic either at the first signs of a subsequent recurrence, when separate swabs were taken from external and internal lesions present, or otherwise every 4 weeks when diary cards were checked and replaced.
They then progressed to the treatment period which continued for 24 weeks. Treatment was commenced 7 days after the start of the first recurrence subsequent to the observation period. Each patient was given two bottles of tablets and instructed to take one tablet from each twice daily. They were randomly assigned to treatment with one of the following: number and severity of HSV episodes were calculated for the patients in each of the three treatment groups. The efficacy and laboratory data were dual entered and edited into a computer database system for analysis. All the summary statistics were produced using the SAS statistical package. The Kaplan-Meier curves were calculated using the SAS procedure PROC LIFETEST.
Results
Number ofpatients A total of 127 patients were entered into the study. Ten patients did not experience a recurrence during the observation period. One withdrew from the study and nine continued in the treatment and follow up periods. Of these five received acyclovir, two received isoprinosine and two received placebo. Thus, a total of 126 patients were included for the efficacy analysis.
Demographic details and baseline characteristics Demographic details and baseline characteristics of patients at entry are summarised in table 1. The three treatment groups were comparable for mean age, sex ratio, and preceding history of recurrent genital herpes.
Number ofpatients reporting recurrent lesions (table 2) During two months observation, the percentages of patients reporting one or more recurrences were 91% in the acyclovir group, 96% in the isoprinosine group and 92% in the placebo group. During the 6 month treatment period, however, the percentage of patients reporting one or more recurrences was 31 % in the acyclovir group, 96% in the isoprinosine group and 79% in the placebo group. The percentage of patients in the acyclovir group was significantly lower (p < 0.05) than the percentages in either the placebo group or the isoprinosine group.
During follow up, the percentage of patients reporting one or more recurrences was 82% in the acyclovir group, 69% in the isoprinosine group and 50% in the placebo group. The difference between the percentages in the acyclovir and isoprinosine groups were not statistically significant, however there were significantly fewer recurrences amongst placebo treated patients (p < 005).
Number of reported recurrent episodes The mean number of reported recurrent infections per patient during the 2 months observation period was similar in all three treatment groups (table 2) .
During treatment, the mean number of reported recurrences per patient was 0.6 in the acyclovir group, 3.6 in the isoprinosine group and 2.5 in the placebo group. These mean values were significantly different (p < 0.05) between all pairs of treatments. In the acyclovir group only 3.6% of patients had three or more reported recurrences compared with 59.2% in the isoprinosine group and 41.7% in the placebo group. Mean duration of recurrences During both the observation and post-treatment periods, there were no differences between the treatment groups with respect to the mean duration of recurrences (table 3) . However, during treatment, the mean duration for the acyclovir group (6.4 days) was significantly shorter (p < 0'05), than for the isoprinosine group (8.2 days).
Mean duration of symptomslerythema
The mean duration of symptoms/erythema (that is, the total number of days per patient, with symptoms and/or erythema, but without lesions) was calculated for each treatment group. The 95% confidence intervals for differences between the means included zero and gave no evidence for any statistically significant differences between any pairs of treatment during the treatment or follow-up periods.
Adverse events In general, all treatments were extremely well tolerated with only six patients reporting 11 .
adverse events, six in the acyclovir group (in 2Wo 300 3so three patients), four in the isoprinosine group (in two patients) and one in the placebo group. follow-up for all patients in These were invariably mild, self-limiting, and of doubtful attributability to drug therapy. Clinical laboratory evaluations The majority of patients did not suffer abi mal biochemical or haematological chan The few detected abnormal values were g erally lower than the expected values, tl were mild, sporadic, did not follow a partic pattern and usually returned to normal.
Discussion
The results of this study are similar to thos previous placebo controlled trials3 wi have confirmed the efficacy of acyclovii suppressing recurrent genital herpes. Isopr sine (Immunovir), an immunomodulator % low toxicity, has in some studies been show reduce the severity and speed of resolutioi mucocutaneous herpes simplex react tions.'2-17 Although it has been claimec reduce the duration of viral shedding and t to healing in patients with primary gei herpes, a recent comparative study sho that acyclovir treated patients had a she duration of symptoms and viral shedding, healed more quickly than those treated isoprinosine.`However, neither prepara appeared to have any effect on the time to recurrence or the frequency of subseqi recurrences.
The efficacy of a high dose isoprino regimen (1 g four times daily) has also E compared with acyclovir 800 mg daily for suppression of frequently recurring ger herpes.`9 In this trial, 100% of patients rec ing isoprinosine experienced recurrences c pared with only 36% of those receiving acy vir experienced recurrences during treatmo
The results of the present study, usin lower comparative dose of isoprinosine, similar. Acyclovir treated patients experien a significantly lower mean number of repo. The results of this study demonstrate that r in acyclovir therapy is substantially more effective ino-than isoprinosine therapy for the suppression with of recurrent genital herpes. Similar results ,n to indicating the superiority of acyclovir for supn of pression of recurrent attacks have now been tiva-shown for studies of both low (1 g) and high 1 to (4 g) daily doses of isoprinosine. Acyclovir is time clearly the treatment of choice for the managenital ment of patients with both first episode and wed recurrent genital herpes. In the latter, the rter choice between episodic treatment with selfand initiated short treatment courses of oral acyclowith vir``or topical 5% acyclovir cream,23 24 tion (both of which are of proven clinical efficacy) first and continuous oral suppression, will depend aent upon individual patient assessment not only of their frequency of episodes but also the other Isine physical, psychological and social effects of )een their recurrent disease. the 
